This filing removes a contractual barrier to buybacks but does not commit the company to repurchasing shares. Monitor future filings for actual repurchase activity and the company's cash position, as the $20 million authorization represents a significant portion of the $32 million market cap. The stock's recent volatility and the company's history of name changes and capital structure changes warrant caution.
Price Chart
Executive Summary
SRX Global Inc. obtained consent from the holders of its Series C convertible preferred stock to implement a stock repurchase plan, allowing the company to buy back up to 10 million shares or 50% of outstanding common stock for up to $20 million through July 2027. This removes a contractual restriction from the August 2026 securities purchase agreement that had prohibited such repurchases, but does not change the company's underlying financial position or operations. The filing is a routine contractual amendment with no new financial data or operational updates.
Key Facts
- SRX Global entered into a Limited Consent and Amendment Agreement with holders of Series C convertible preferred stock on September 8, 2026.
- The consent allows SRXH to maintain a stock repurchase plan to buy back up to the lesser of 10 million shares or 50% of outstanding common stock, for up to $20 million, through July 7, 2027.
- The Series C preferred stock was issued on August 27, 2026, for $2.825 million (3,579 shares).
- The consent waives restrictions in the Securities Purchase Agreement and Certificate of Designations that had prohibited stock repurchases.
- The company will reimburse the holder's counsel $5,000 for costs related to the agreement.
Financial Impact
Authorizes up to $20 million in share repurchases, but no actual repurchases have been announced or executed.
Risk Factors
- The repurchase plan is authorized but not yet executed; no shares have been bought back.
- The company has a history of name changes (SRx Health Solutions, Better Choice Co Inc., Sport Endurance) and a small market cap ($32M), indicating potential volatility.
- The Series C preferred stock terms and the consent agreement may contain additional restrictions or conversion rights not fully detailed in this filing.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (SRXH) — Batch item 1 | 0001493152-26-041945 |
| Exhibit: ex10-1.htm | 0001493152-26-041945 |
| Document: 0001493152-26-041945-index-headers.html | 0001493152-26-041945 |
| Document: 0001493152-26-041945-index.html | 0001493152-26-041945 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 9, 2026 23d ago | 8-K | $1.51 $1.60 | ▲ +5.96% | ▲ +6.62% | $1.61 (+6.62%) |
Sep 2, 2026 4w ago | 8-K | $1.56 $1.59 | ▲ +1.92% | ▲ +3.07% | $1.61 (+3.21%) |
Aug 28, 2026 5w ago | 8-K | $1.68 $1.59 | ▲ +5.65% | ▲ +5.51% | $1.61 (+4.17%) |
Aug 19, 2026 6w ago | 8-K | $1.87 $1.84 | ▼ −1.60% | ▼ −1.22% | $1.61 (−13.90%) |
Aug 4, 2026 8w ago | Press Release | $1.37 $1.84 | ▲ +34.31% | ▲ +34.41% | $1.61 (+17.52%) |
Aug 3, 2026 8w ago | Press Release | $1.44 $1.73 | ▲ +20.14% | ▲ +18.11% | $1.61 (+11.81%) |
Jul 30, 2026 9w ago | Press Release | $1.48 $1.43 | ▼ −3.38% | ▼ −7.00% | $1.61 (+8.78%) |
Jul 28, 2026 9w ago | 8-K | $1.48 $1.44 | ▲ +2.70% | ▲ +4.97% | $1.61 (−8.78%) |
Jul 16, 2026 11w ago | 8-K | $2.41 $1.80 | ▼ −25.31% | ▼ −23.64% | $1.61 (−33.20%) |
Jul 16, 2026 11w ago | Press Release | $2.41 $1.80 | ▼ −25.31% | ▼ −23.64% | $1.61 (−33.20%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access